

**RECEIVED**

Date of Facsimile: November 9, 2005

CENTRAL FAX CENTER Attorney Docket No.: CST-201 CIP

PAIR Customer No.: 31012

**NOV 09 2005****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Rush *et al*  
ASSIGNEE: CELL SIGNALING TECHNOLOGY, INC.  
SERIAL NUMBER: 10/777,893 EXAMINER: P. Do  
FILING DATE: February 12, 2004 ART UNIT: 1641  
FOR: IMMUNOAFFINITY ISOLATION OF MODIFIED PEPTIDES FROM  
COMPLEX MIXTURES

November 9, 2005  
Beverly, Massachusetts

Mail Stop AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

**U.S. Patent or Application Documents:****Foreign Patent Documents:****Other Prior Art – Non Patent Literature Documents:**

Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
Quadroni, et al., <i>Proteomics in functional Genomics</i> , 2000; 88: 199-213. Review.

APPLICANTS: Rush *et al*  
U.S.S.N.: 10/777,893

Attorney Docket No: CST-201 CIP

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☐ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. 37 C.F.R. §1.97.

This Information Disclosure Statement is being filed:

- ☒ after the mailing of a first Office Action on the merits, but before the mailing date of a final Office Action, a Notice of Allowance, or an action that otherwise closes prosecution in the application; and

- ☒ is accompanied by the following statement:

☐ Applicant(s) hereby state(s) that each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement (37 C.F.R. §1.97(e)(1)); or

☒ Applicant(s) hereby state(s) that no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned representative signing this certification after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in Rule 1.56(c) more than three months prior to the filing of this information disclosure (37 C.F.R. §1.97(e)(2)); and

- ☐ is accompanied by the fee set forth in 37 C.F.R. §1.17(p):

- ☐ a check for the required fee is enclosed herewith; or
- ☒ the Commissioner is hereby authorized to charge the required fee (and any other fees that may be due) to U.S. Deposit Account No. 50-1774, Ref. No. CST-201 CIP.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS: Rush *et al*  
U.S.S.N.: 10/777,893

Attorney Docket No: CST-201 CIP

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-1774, Reference No. CST-201 CIP.

Respectfully submitted,



James Gregory Cullem, J.D., Reg. No. 43,569  
Intellectual Property Counsel  
CELL SIGNALING TECHNOLOGY, INC.

Dated: 11/9/05

Date of Facsimile: November 9, 2005

Attorney Docket No.: CST-201 CIP  
PAIR Customer No.: 31012

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Application Number	10/777,893
	Filing Date	February 12, 2004
	First Named Inventor	Rush <i>et al.</i>
	Group Art Unit	1641
	Examiner Name	P. Do
	Attorney Docket Number	CST-201 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate

U.S. CO-PENDING PATENT APPLICATIONS							
Exam Initials	Cite No.	U.S. Patent App. Serial No.	Status	Name of Applicant(s) and Assignee	Art Unit	Examiner	Filing Date

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	DA	Quadroni, et al., <i>Proteomics in Functional Genomics</i> , 2000; 88: 199-213. Review.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 09/535,364, filed March 24, 2000, U.S.S.N. 09/148,712, filed September 4, 1998, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Date of Facsimile: November 9, 2005

Attorney Docket No.: CST-201 CIP  
PAIR Customer No.: 31012

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Application Number	10/777,893
	Filing Date	February 12, 2004
	First Named Inventor	Rush <i>et al.</i>
	Group Art Unit	1641
	Examiner Name	P. Do
	Attorney Docket Number	CST-201 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. CO-PENDING PATENT APPLICATIONS							
Exam Initials	Cite No.	U.S. Patent App. Serial No.	Status	Name of Applicant(s) and Assignee	Art Unit	Examiner	Filing Date

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	DA	Quadroni, et al., <i>Proteomics in Functional Genomics</i> , 2000; 88: 199-213. Review.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 09/535,364, filed March 24, 2000, U.S.S.N. 09/148,712, filed September 4, 1998, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.